Literature DB >> 28090795

Isolation and characterization of anti c-met single chain fragment variable (scFv) antibodies.

Elmira Safaie Qamsari1,2,3, Zahra Sharifzadeh3, Salman Bagheri1,2,3, Farhad Riazi-Rad4, Vahid Younesi5, Mohsen Abolhassani3, Sepideh Safaei Ghaderi6, Behzad Baradaran1, Mohammad Hossein Somi7, Mehdi Yousefi7.   

Abstract

The receptor tyrosine kinase (RTK) Met is the cell surface receptor for hepatocyte growth factor (HGF) involved in invasive growth programs during embryogenesis and tumorgenesis. There is compelling evidence suggesting important roles for c-Met in colorectal cancer proliferation, migration, invasion, angiogenesis, and survival. Hence, a molecular inhibitor of an extracellular domain of c-Met receptor that blocks c-Met-cell surface interactions could be of great thera-peutic importance. In an attempt to develop molecular inhibitors of c-Met, single chain variable fragment (scFv) phage display libraries Tomlinson I + J against a specific synthetic oligopeptide from the extracellular domain of c-Met receptor were screened; selected scFv were then characterized using various immune techniques. Three c-Met specific scFv (ES1, ES2, and ES3) were selected following five rounds of panning procedures. The scFv showed specific binding to c-Met receptor, and significantly inhibited proliferation responses of a human colorectal carcinoma cell line (HCT-116). Moreover, anti- apoptotic effects of selected scFv antibodies on the HCT-116 cell line were also evaluated using Annexin V/PI assays. The results demonstrated rates of apoptotic cell death of 46.0, 25.5, and 37.8% among these cells were induced by use of ES1, ES2, and ES3, respectively. The results demonstrated ability to successfully isolate/char-acterize specific c-Met scFv that could ultimately have a great therapeutic potential in immuno-therapies against (colorectal) cancers.

Entities:  

Keywords:  HGF; c-Met; colorectal cancer; phage display; scFv

Mesh:

Substances:

Year:  2017        PMID: 28090795     DOI: 10.1080/1547691X.2016.1251512

Source DB:  PubMed          Journal:  J Immunotoxicol        ISSN: 1547-691X            Impact factor:   3.000


  5 in total

1.  A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer.

Authors:  Amita Patnaik; Michael Gordon; Frank Tsai; Kyriakos P Papadopoulos; Drew Rasco; Muralidhar Beeram; Siqing Fu; Filip Janku; Scott M Hynes; Sushma R Gundala; Melinda D Willard; Wei Zhang; Aimee Bence Lin; David Hong
Journal:  Cancer Chemother Pharmacol       Date:  2018-06-20       Impact factor: 3.333

2.  Construction and preliminary identification of a prokaryotic expression single-chain antibody fragments library against Streptococcus pneumoniae from antibody-producing cells in human tonsil.

Authors:  Jiaqi Luo; Lu Yang; Zhen Long; Zhiwen Xiao; Xiaomei Sun; Shimin Zhuang; Liangen Xie; Wei Wang; Guanping Zhang; Yue Qu; Tianrun Liu
Journal:  Bioengineered       Date:  2019-12       Impact factor: 3.269

3.  Preparation of a Novel One-Armed Anti-c-Met Antibody with Antitumor Activity Against Hepatocellular Carcinoma.

Authors:  Yanxin Yin; Jia Guo; Fei Teng; Lihua Yu; Yun Jiang; Kun Xie; Ming Jiang; Jianmin Fang
Journal:  Drug Des Devel Ther       Date:  2019-12-10       Impact factor: 4.162

4.  Development of a human phage display-derived anti-PD-1 scFv antibody: an attractive tool for immune checkpoint therapy.

Authors:  Sepideh Safaei Ghaderi; Farhad Riazi-Rad; Elmira Safaie Qamsari; Salman Bagheri; Fatemeh Rahimi-Jamnani; Zahra Sharifzadeh
Journal:  BMC Biotechnol       Date:  2022-08-23       Impact factor: 3.329

5.  Targeting the 4-1BB costimulatory molecule through single chain antibodies promotes the human T-cell response.

Authors:  Salman Bagheri; Elmira Safaie Qamsari; Mehdi Yousefi; Farhad Riazi-Rad; Zahra Sharifzadeh
Journal:  Cell Mol Biol Lett       Date:  2020-04-22       Impact factor: 5.787

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.